Fulgent buys CSI Laboratories to expand cancer testing capabilities
The acquisition of CSI will allow Fulgent to significantly expand its capabilities in molecular diagnostics and oncologic testing
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Aug 21
The acquisition of CSI will allow Fulgent to significantly expand its capabilities in molecular diagnostics and oncologic testing
10 Aug 21
New test helps people understand their body's response to Covid vaccine
10 Aug 21
Pala Diagnostics will provide laboratory mobile concierge service for businesses, conventions, hospitality, and schools
09 Aug 21
The rapid portable test holds the capacity to identify SARS-CoV-2 antigen in people with active infections in two…
09 Aug 21
New Test Kit Aids in Identifying the Presence of Cancerous or Precancerous Growths in the Colon Aims to…
05 Aug 21
The test can be self-administered by the users or with the help of a healthcare professional and provides…
05 Aug 21
Immunovia AB is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune…
04 Aug 21
Philips and NYU Langone Health Department of Pathology, a premier NCI (National Cancer Institute) designated comprehensive cancer center,…
03 Aug 21
InterVenn intends to use the funding to expand its AI-driven glycoproteomics platform and its liquid biopsy assay dubbed…
29 Jul 21
The financing will help advance the development of Strata’s personalised minimal residual disease assay for early-stage cancers